Abexinostat

Abexinostat

Names
IUPAC name 3-[(Dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide
Other names PCI-24781; CRA-024781
Identifiers
CAS Number	783355-60-2 N 783356-67-2 (HCl) Y
3D model (Jmol)	Interactive image
ChemSpider	9924562 Y
KEGG	D10060 N
PubChem CID	11749858
UNII	IYO470654U N
InChI InChI=1S/C21H23N3O5/c1-24(2)13-17-16-5-3-4-6-18(16)29-19(17)21(26)22-11-12-28-15-9-7-14(8-10-15)20(25)23-27/h3-10,27H,11-13H2,1-2H3,(H,22,26)(H,23,25) Y Key: MAUCONCHVWBMHK-UHFFFAOYSA-N Y InChI=1/C21H23N3O5/c1-24(2)13-17-16-5-3-4-6-18(16)29-19(17)21(26)22-11-12-28-15-9-7-14(8-10-15)20(25)23-27/h3-10,27H,11-13H2,1-2H3,(H,22,26)(H,23,25) Key: MAUCONCHVWBMHK-UHFFFAOYAM
SMILES O=C(NO)c3ccc(OCCNC(=O)c2oc1ccccc1c2CN(C)C)cc3
Properties
Chemical formula	C21H23N3O5
Molar mass	397.43 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N  (what is YN ?)
Infobox references

Abexinostat (INN, formerly PCI-24781) is an experimental drug candidate for cancer treatment. It is currently under development by Pharmacyclics and is in Phase II clinical trials for B-cell lymphoma. Pre-clinical study suggests the potential for treatment of different types of cancer as well.

Abexinostat exerts its effect as a histone deacetylase inhibitor.